{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T21:46:44Z","timestamp":1649022404345},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T00:00:00Z","timestamp":1361577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00198-013-2301-1","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T10:28:44Z","timestamp":1361528924000},"page":"2353-2357","source":"Crossref","is-referenced-by-count":1,"title":["Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate"],"prefix":"10.1007","volume":"24","author":[{"given":"M. P.","family":"Yavropoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A. T.","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,23]]},"reference":[{"key":"2301_CR1","doi-asserted-by":"crossref","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C, The IOF CSA Inadequate Responders Working Group (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769\u201374. doi: 10.1007\/s00198-012-2093-8","DOI":"10.1007\/s00198-012-2093-8"},{"key":"2301_CR2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1359\/jbmr.060715","volume":"21","author":"S Adami","year":"2006","unstructured":"Adami S, Isaia G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565\u20131570","journal-title":"J Bone Miner Res"},{"key":"2301_CR3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jbmr.1496","volume":"27","author":"A D\u00edez-P\u00e9rez","year":"2012","unstructured":"D\u00edez-P\u00e9rez A, Olmos JM, Nogu\u00e9s X, Sosa M, D\u00edaz-Curiel M, P\u00e9rez-Castrill\u00f3n JL, P\u00e9rez-Cano R, Mu\u00f1oz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonz\u00e1lez-Mac\u00edas J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817\u2013824","journal-title":"J Bone Miner Res"},{"key":"2301_CR4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0002-9343(85)90055-5","volume":"79","author":"RD Altman","year":"1985","unstructured":"Altman RD (1985) Long-term follow-up of therapy with intermittent etidronate disodium in Paget\u2019s disease of bone. Am J Med 79:583\u2013590","journal-title":"Am J Med"},{"key":"2301_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jbmr.5650140216","volume":"14","author":"DH Gutteridge","year":"1999","unstructured":"Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S (1999) Paget\u2019s disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14:79\u201384","journal-title":"J Bone Miner Res"},{"key":"2301_CR6","first-page":"467","volume":"66","author":"A Trombetti","year":"1999","unstructured":"Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget\u2019s disease of bone. Rev Rhum Engl Ed 66:467\u2013476","journal-title":"Rev Rhum Engl Ed"},{"issue":"Suppl 2","key":"2301_CR7","doi-asserted-by":"crossref","first-page":"P88","DOI":"10.1359\/jbmr.06s216","volume":"21","author":"SE Papapoulos","year":"2006","unstructured":"Papapoulos SE, Eekhoff EM, Zwinderman AH (2006) Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res 21(Suppl 2):P88\u201391","journal-title":"J Bone Miner Res"},{"key":"2301_CR8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u201399","journal-title":"N Engl J Med"},{"key":"2301_CR9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u20138","journal-title":"Calcif Tissue Int"},{"key":"2301_CR10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6\u00a0years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u201354","journal-title":"J Bone Miner Res"},{"key":"2301_CR11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","volume":"23","author":"PD Miller","year":"2012","unstructured":"Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5\u00a0years: the MOBILE long-term extension study. Osteoporos Int 23:1747\u201356","journal-title":"Osteoporos Int"},{"key":"2301_CR12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00776-008-1265-z","volume":"13","author":"K Iba","year":"2008","unstructured":"Iba K, Takada J, Hatakeyama N, Ozasa Y, Wada T, Yamashita T (2008) Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment. J Orthop Sci 13:438\u201341","journal-title":"J Orthop Sci"},{"key":"2301_CR13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bone.2003.07.007","volume":"33","author":"ER Beek van","year":"2003","unstructured":"van Beek ER, Cohen LH, Leroy IM, Ebetino FH, L\u00f6wik CW, Papapoulos SE (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805\u201311","journal-title":"Bone"},{"key":"2301_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2710.2004.00584.x","volume":"29","author":"E Cauza","year":"2004","unstructured":"Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A (2004) Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 29:431\u20136","journal-title":"J Clin Pharm Ther"},{"key":"2301_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MAJ.0b013e3181c7c89c","volume":"339","author":"MV Hern\u00e1ndez","year":"2010","unstructured":"Hern\u00e1ndez MV, Peris P, Monegal A, Reyes R, Muxi A, Gifre L, Gua\u00f1abens N (2010) Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. Am J Med Sci 339:225\u20139","journal-title":"Am J Med Sci"},{"key":"2301_CR16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bone.2009.01.371","volume":"44","author":"P Makras","year":"2009","unstructured":"Makras P, Hamdy NAT, Zwinderman AH, Ballieux BEPB, Papapoulos SE (2009) Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone 44:766\u201371","journal-title":"Bone"},{"key":"2301_CR17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5\u00a0mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u20138","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2301-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2301-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2301-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:08:52Z","timestamp":1558624132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2301-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,23]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2301-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,23]]}}}